BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
as the company agreed to acquire Amicus Therapeutics for a total equity value of about $4.8 billion, a move expected to boost future growth. BioMarin's President and CEO, Alexander Hardy, said the transaction was expected to accelerate the company's revenue growth and strengthen its financial outlook. The deal was viewed positively by analysts, with Truist Securities raising its price target on the stock to $100 from $80, noting the acquisition aligned with BioMarin's focus on rare diseases. In other news, the company also announced it had stopped the development of its investigational BMN 349 treatment for a specific type of liver disease. After the initial pop the shares cooled down to $60.97, up 2.9% from previous close. Is now the time to buy BioMarin Pharmaceutical? Access our full analysis report here BioMarin Pharmaceutical's shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today's move indicates the market consid
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.MarketBeat
- Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.MarketBeat
- Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/23/25 - Form 4
- 12/19/25 - Form 144
- 12/19/25 - Form DEFA14A
- FOLD's page on the SEC website